Submitted:
30 August 2023
Posted:
01 September 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Analytic strategy
3. Specific key points in attention deficit hyperactivity disorder
4. Key points in diagnosis
5. Differential diagnosis
6. Treatment key points
7. Management directions
8. Conclusion
References
- Goodwin, R.D.; Sourander, A.; Duarte, C.S.; Niemelä, S.; Multimäki, P.; Nikolakaros, G.; Helenius, H.; Piha, J.; Kumpulainen, K.; Moilanen, I.; et al. Do mental health problems in childhood predict chronic physical conditions among males in early adulthood? Evidence from a community-based prospective study. Psychol. Med. 2008, 39, 301–311. [Google Scholar] [CrossRef]
- Brito, N.H.; Noble, K.G. Socioeconomic status and structural brain development. Front. Neurosci. 2014, 8, 276. [Google Scholar] [CrossRef]
- Champagne, F.A. Nurturing Nature: Social Experiences and the Brain. J. Neuroendocr. 2009, 21, 867–868. [Google Scholar] [CrossRef] [PubMed]
- Gallo, E.F.; Posner, J. Moving towards causality in attention-deficit hyperactivity disorder: overview of neural and genetic mechanisms. Lancet Psychiatry 2016, 3, 555–567. [Google Scholar] [CrossRef] [PubMed]
- Shonkoff, J.P.; Richter, L.; van der Gaag, J.; Bhutta, Z.A. An Integrated Scientific Framework for Child Survival and Early Childhood Development. PEDIATRICS 2012, 129, e460–e472. [Google Scholar] [CrossRef] [PubMed]
- Fleming, T.P.; Watkins, A.J.; Velazquez, M.A.; Mathers, J.C.; Prentice, A.M.; Stephenson, J.; Barker, M.; Saffery, R.; Yajnik, C.S.; Eckert, J.J.; et al. Origins of lifetime health around the time of conception: causes and consequences. Lancet 2018, 391, 1842–1852. [Google Scholar] [CrossRef]
- A Bhutta, Z.; Chopra, M.; Axelson, H.; Berman, P.; Boerma, T.; Bryce, J.; Bustreo, F.; Cavagnero, E.; Cometto, G.; Daelmans, B.; et al. Countdown to 2015 decade report (2000–10): taking stock of maternal, newborn, and child survival. Lancet 2010, 375, 2032–2044. [Google Scholar] [CrossRef]
- Rubin, DB. Multiple imputation in sample surveys: A phenomenological Bayesian approach to nonresponse. Proceedings of the survey research methods section of the American Statistical Association. 1978:20–34.
- Allison, PD. Missing data. Thousand Oaks, CA: Sage; 2001.
- Wilens, T.E.; Spencer, T.J. Understanding Attention-Deficit/Hyperactivity Disorder from Childhood to Adulthood. Postgrad. Med. 2010, 122, 97–109. [Google Scholar] [CrossRef]
- Steingard, R.; Taskiran, S.; Connor, D.F.; Markowitz, J.S.; Stein, M.A. New Formulations of Stimulants: An Update for Clinicians. J. Child Adolesc. Psychopharmacol. 2019, 29, 324–339. [Google Scholar] [CrossRef]
- van der Burg D, Crunelle CL, Matthys F, van den Brink W. Diagnosis and treatment of patients with comorbid substance use disorder and adult attention-deficit and hyperactivity disorder: a review of recent publications. Curr Opin Psychiatry 2019, 32, 300–306. [CrossRef]
- Cortese, S.; Coghill, D. Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward. Évid. Based Ment. Heal. 2018, 21, 173–176. [Google Scholar] [CrossRef] [PubMed]
- Salvi, V.; Migliarese, G.; Venturi, V.; Rossi, F.; Torriero, S.; Viganò, V.; Cerveri, G.; Mencacci, C. ADHD in adults: clinical subtypes and associated characteristics. Riv Psichiatr 2019, 54, 84–89. [Google Scholar] [PubMed]
- Mikami, A.Y.; Miller, M.; Lerner, M.D. Social functioning in youth with attention-deficit/hyperactivity disorder and autism spectrum disorder: transdiagnostic commonalities and differences. Clin. Psychol. Rev. 2019, 68, 54–70. [Google Scholar] [CrossRef]
- Leahy, L.G. Diagnosis and treatment of ADHD in children vs adults: What nurses should know. Arch. Psychiatr. Nurs. 2018, 32, 890–895. [Google Scholar] [CrossRef] [PubMed]
- Brikell I, Chen Q, Kuja-Halkola R, D'Onofrio BM, Wiggs KK, Lichtenstein P, Almqvist C, Quinn PD, Chang Z, Larsson H. Medication treatment for attention-deficit/hyperactivity disorder and the risk of acute seizures in individuals with epilepsy. Epilepsia 2019, 60, 284–293. [CrossRef] [PubMed]
- Fosi, T.; Lax-Pericall, M.T.; Scott, R.C.; Neville, B.G.; Aylett, S.E. Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: Evidence of clinical benefit. Epilepsia 2013, 54, 2071–2081. [Google Scholar] [CrossRef]
- Cortese, S.; Coghill, D. Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward. Évid. Based Ment. Heal. 2018, 21, 173–176. [Google Scholar] [CrossRef]
- Salvi, V.; Migliarese, G.; Venturi, V.; Rossi, F.; Torriero, S.; Viganò, V.; Cerveri, G.; Mencacci, C. ADHD in adults: clinical subtypes and associated characteristics. Riv Psichiatr 2019, 54, 84–89. [Google Scholar]
- Mikami, A.Y.; Miller, M.; Lerner, M.D. Social functioning in youth with attention-deficit/hyperactivity disorder and autism spectrum disorder: transdiagnostic commonalities and differences. Clin. Psychol. Rev. 2019, 68, 54–70. [Google Scholar] [CrossRef]
- Leahy, L.G. Diagnosis and treatment of ADHD in children vs adults: What nurses should know. Arch. Psychiatr. Nurs. 2018, 32, 890–895. [Google Scholar] [CrossRef]
- Feldman ME, Charach A, Bélanger SA. ADHD in children and youth: Part 2—Treatment. Paediatr Child Health 2018, 23, 462–472. [CrossRef] [PubMed]
- Connor, D.F.; Steingard, R.J. New Formulations of Stimulants for Attention-Deficit Hyperactivity Disorder. CNS Drugs 2004, 18, 1011–1030. [Google Scholar] [CrossRef] [PubMed]
- Stein, M.A.; Waldman, I.D.; Charney, E.; Aryal, S.; Sable, C.; Gruber, R.; Newcorn, J.H. Dose Effects and Comparative Effectiveness of Extended Release Dexmethylphenidate and Mixed Amphetamine Salts. J. Child Adolesc. Psychopharmacol. 2011, 21, 581–588. [Google Scholar] [CrossRef] [PubMed]
- Patrick, K.S.; A González, M.; Straughn, A.B.; Markowitz, J.S. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin. Drug Deliv. 2005, 2, 121–143. [Google Scholar] [CrossRef]
- Patrick KS, Radke JL, Raymond JR, Koller L, Nguyen LV, Rodriguez W, Straughn AB. Drug regimen individualization for attention-deficit/hyperactivity disorder: Guidance for methylphenidate and dexmethylphenidate formulations. Pharmacotherapy 2018.
- Patrick, K.S.; Straughn, A.B.; Perkins, J.S.; González, M.A. Evolution of stimulants to treat ADHD: transdermal methylphenidate. Hum. Psychopharmacol. Clin. Exp. 2008, 24, 1–17. [Google Scholar] [CrossRef] [PubMed]
- Quinn, D. Does chirality matter?: Pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008, 28, S62–S66. [Google Scholar] [CrossRef] [PubMed]
- Zhu, H.-J.; Patrick, K.S.; Yuan, H.-J.; Wang, J.-S.; Donovan, J.L.; DeVane, C.L.; Malcolm, R.; Johnson, J.A.; Youngblood, G.L.; Sweet, D.H.; et al. Two CES1 Gene Mutations Lead to Dysfunctional Carboxylesterase 1 Activity in Man: Clinical Significance and Molecular Basis. Am. J. Hum. Genet. 2008, 82, 1241–1248. [Google Scholar] [CrossRef]
- Adler, L.A.; Frick, G.; Yan, B. A Long-Term, Open-Label, Safety Study of Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD. J. Atten. Disord. 2017, 24, 434–446. [Google Scholar] [CrossRef]
- Adler, L.D.; Nierenberg, A.A. ; Ba; Md Review of Medication Adherence in Children and Adults with ADHD. Postgrad. Med. 2010, 122, 184–191. [Google Scholar] [CrossRef]
- FDA. Center for Drug Evaluation and Research, Benzedrine® medical review: Application Number: 83900. 1976a. https://wwwaccessdatafdagov/drugsatfda_docs/anda/pre96/83900_Amphetamine%20Sulfate_Medrpdf Accessed March13, 2019.
- FDA. Dexedrine®, Product Monograph, Application Number:ANDA084935. 1976b. https://wwwaccessdatafdagov/drugsatfda_docs/label/2007/017078s042lblpdf Accessed March13, 2019.
- FDA. Center for Drug Evaluation and Research; Methylin Oral Solution® medical review: Application Number: 21–419. 2002a. https://wwwaccessdatafdagov/drugsatfda_docs/nda/2002/21–419_Methylin_Medrpdf Accessed March13, 2019.
- FDA. Center for Drug Evaluation and Research; Methylin® Oral Solution clinical pharmaceuticals and biopharmaceuticals review: Application Number: 021419. 2002b. https://wwwaccessdatafdagov/drugsatfda_docs/nda/2002/21–419_Methylin_BioPharmrpdf Accessed March13, 2019.
- FDA. Center for Drug Evaluation and Research; Methylin® Chewable Tablet clinical pharmaceuticals and biopharmaceuticals review: Application Number: 021475, 2003. 2003a. https://wwwaccessdatafdagov/drugsatfda_docs/nda/2003/021475s000_Methylin_Chewables_ClinPharmRpdf Accessed March13, 2019.
- FDA. Center for Drug Evaluation and Research; Daytrana® clinical pharmaceuticals and biopharmaceuticals review (Part 1): Application Number: 021514s000. 2006a. https://wwwaccessdatafdagov/drugsatfda_docs/nda/2006/021514s000_ClinPharmR_P1pdf Accessed March13, 2019.
- FDA. Center for Drug Evaluation and Research; Daytrana® clinical pharmaceuticals and biopharmaceuticals review (Part 2): Application Number: 021514s000. 2006b. https://wwwaccessdatafdagov/drugsatfda_docs/nda/2006/021514s000_ClinPharmR_P2pdf Accessed March13, 2019.
- FDA. Center for Drug Evaluation and Research; Daytrana® medical review (Part 1): Application Number: 021514s000. 2006c. https://wwwaccessdatafdagov/drugsatfda_docs/nda/2006/021514s000_MedR_P1pdf Accessed March13, 2019.
- FDA. Center for Drug Evaluation and Research; Daytrana® medical review (Part 2): Application Number: 021514s000. 2006d. https://wwwaccessdatafdagov/drugsatfda_docs/nda/2006/021514s000_MedR_P2pdf Accessed March13, 2019.
- Arnold, L.; Bozzolo, D.; Hodgkins, P.; McKay, M.; Beckett-Thurman, L.; Greenbaum, M.; Bukstein, O.; Patel, A. Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Curr. Med Res. Opin. 2009, 26, 129–137. [Google Scholar] [CrossRef]
- Findling, R.L.; Dinh, S. Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS). CNS Drugs 2014, 28, 217–28. [Google Scholar] [CrossRef] [PubMed]
- Pastore, M.N.; Kalia, Y.N.; Horstmann, M.; Roberts, M.S. Transdermal patches: history, development and pharmacology. Br. J. Pharmacol. 2015, 172, 2179–2209. [Google Scholar] [CrossRef] [PubMed]


Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).